Organon & Co. business relationships
Companies named in Organon & Co.’s 10-K filed 2026-02-24, and public companies whose annual reports name Organon & Co.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.6 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Organon & Co.’s annual report 8
“Under the terms of the agreement with Biogen, we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solution...” SEC filing
“• Other agreements that Organon entered into with Merck include the Intellectual Property License Agreements and Regulatory Agreements.” SEC filing
“• Manufacturing and Supply Agreements - Merck and Organon and/or their applicable affiliates entered into a number of manufacturing and supply agreements pursuant to which the relevant Merck entity (a) manufactures and supplies certain active pharmaceutical ingredients for the relevant Organon entit...” SEC filing
“In December 2023, Organon announced an agreement with Lilly to become the sole distributor and promoter of the migraine medicine Emgality in Europe.” SEC filing
“The Company's customers with the largest accounts receivable balances are McKesson Corporation and Cencora, Inc., which represented approximately 14 % and 7 %, respectively, of total gross accounts receivable at December 31, 2025.” SEC filing
“The Company's customers with the largest accounts receivable balances are McKesson Corporation and Cencora, Inc., which represented approximately 14 % and 7 %, respectively, of total gross accounts receivable at December 31, 2025.” SEC filing
“In accordance with a settlement and license agreement with Genentech, Inc. and related parties ("Genentech") that grants license rights under Genentech's intellectual property to commercialize HLX11, the Company intends to launch HLX11 in the United States in late 2028.” SEC filing
“...we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the product developer for Tofidence .” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.